Benzinga · Mar 4, 2026
PL
NASDAQ · PLSE
Pulse Biosciences, Inc.
Healthcare · Medical - Instruments & Supplies
$53.81
Up+$3.83 (+7.66%)
Updated Oct 11, 2026, 12:22 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 933.16M
- P/E ratio
- -13.62
- Dividend yield
- 0.00%
- 52-week range
- $12.56 – $58.90
- Volume
- 367.6K
- Avg. volume
- 185.65K
Price performance · PLSE
PLSE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
PLSE closed at $53.81 after 21 trading sessions, up 1.32% for the selected period.
- Last close
- $53.81
- Period change
- +1.32%
- Period low
- $47.90
- Period high
- $55.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $49.98 | $53.97 | $49.98 | $53.81 | 367.6K |
| Oct 8, 2026 | $48.90 | $50.32 | $47.31 | $49.98 | 315.59K |
| Oct 7, 2026 | $49.11 | $49.93 | $48.13 | $49.09 | 409.47K |
| Oct 6, 2026 | $51.26 | $51.26 | $48.62 | $49.75 | 421.37K |
| Oct 5, 2026 | $47.89 | $50.99 | $47.47 | $50.50 | 433.45K |
| Oct 2, 2026 | $50.13 | $50.7122 | $47.7532 | $47.90 | 519.27K |
| Oct 1, 2026 | $49.49 | $51.56 | $49.12 | $49.83 | 450.35K |
| Sep 30, 2026 | $51.18 | $51.27 | $49.17 | $49.92 | 604.61K |
| Sep 29, 2026 | $52.24 | $52.74 | $48.92 | $50.89 | 516.99K |
| Sep 28, 2026 | $51.63 | $53.60 | $51.14 | $52.32 | 374.81K |
| Sep 25, 2026 | $52.17 | $54.05 | $50.8009 | $51.63 | 663.99K |
| Sep 24, 2026 | $52.18 | $53.605 | $51.6221 | $51.83 | 666.97K |
| Sep 23, 2026 | $53.75 | $56.74 | $51.87 | $51.98 | 550.63K |
| Sep 22, 2026 | $53.23 | $53.7867 | $52.485 | $52.69 | 372.19K |
| Sep 21, 2026 | $53.97 | $54.8099 | $51.74 | $53.31 | 382.26K |
| Sep 18, 2026 | $50.61 | $54.29 | $50.245 | $53.87 | 867.54K |
| Sep 17, 2026 | $49.46 | $53.55 | $49.01 | $50.61 | 571.89K |
| Sep 16, 2026 | $52.55 | $54.2405 | $48.61 | $49.61 | 1.04M |
| Sep 15, 2026 | $54.415 | $56.61 | $53.51 | $55.20 | 472.34K |
| Sep 14, 2026 | $52.30 | $55.78 | $51.60 | $54.21 | 505.83K |
| Sep 11, 2026 | $54.50 | $56.6099 | $50.315 | $53.11 | 664.33K |
Latest PLSE news
The latest Smart Investors Daily articles mentioning PLSE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PLSE research
Overview
Company profile and research snapshot.
Company profile
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Canaccord Genuity | Buy | — |
| Sep 23, 2026 | BTIG | Buy | — |
| Sep 9, 2026 | Freedom Capital Markets | Buy | — |
| Aug 17, 2026 | Needham | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 20, 2026
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
ChartMill · Feb 19, 2026
Pulse Biosciences Inc (NASDAQ:PLSE) Narrows Q4 Loss, Beats Revenue Estimates
Pulse Biosciences narrows Q4 losses and beats revenue estimates, advancing key clinical trials for its bioelectric cardiac ablation technology.
Benzinga · Feb 19, 2026
Pulse Biosciences May Offer Up To $59.976M Common Shares
SEC.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
